Afaxys, Inc., a healthcare company committed to advancing reproductive health for public health professionals and their patients, has raised $8 million in funding from two major foundations. The investment includes a $3 million program-related investment (PRI) from the David and Lucile Packard Foundation and a $5 million grant from an anonymous donor. This marks the third contribution from the Packard Foundation since the company's inception in 2008, highlighting continued support and trust in Afaxys’ impact-oriented model.
“Through our mission-based investments, Afaxys has grown into a durable and financially sustainable force in the market that will continue to actively ensure and continually expand reproductive health access for all patients, especially those served by public health providers,” stated Susan Phinney-Silver, Mission Investing Director at the David and Lucile Packard Foundation.
This funding milestone supports a broader growth strategy focused on expanding access to affordable contraception for millions of women in the United States. Afaxys remains the only organization with a nationwide distribution network dedicated to public health clinics, playing a vital role in maintaining reliable supply chains for providers serving Medicaid and Title X patients.
The newly secured capital will advance the final stages of development for an innovative contraceptive product tailored to the needs of underserved communities, including more than 19 million women living in contraceptive deserts.
“Access to quality reproductive healthcare has never been more critical. We are excited to partner with these esteemed foundations to further the Afaxys mission and ensure that access to reproductive healthcare is a right, not a privilege,” said Ronda Dean, CEO of Afaxys, Inc.